Pliant Therapeutics (PLRX) Competitors $1.57 -0.02 (-1.26%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 07/25/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, AMRN, and INBXShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), Amarin (AMRN), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Benitec Biopharma Gossamer Bio COMPASS Pathways Prothena Altimmune Aura Biosciences Cartesian Therapeutics Capricor Therapeutics Amarin Inhibrx Biosciences Benitec Biopharma (NASDAQ:BNTC) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability. Which has more volatility & risk, BNTC or PLRX? Benitec Biopharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Does the media prefer BNTC or PLRX? In the previous week, Benitec Biopharma had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Benitec Biopharma and 2 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.94 beat Benitec Biopharma's score of 0.83 indicating that Pliant Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, BNTC or PLRX? Benitec Biopharma has higher revenue and earnings than Pliant Therapeutics. Benitec Biopharma is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K3,668.44-$21.75M-$1.51-7.40Pliant TherapeuticsN/AN/A-$210.30M-$3.61-0.43 Do analysts recommend BNTC or PLRX? Benitec Biopharma presently has a consensus price target of $26.00, suggesting a potential upside of 132.56%. Pliant Therapeutics has a consensus price target of $13.31, suggesting a potential upside of 747.93%. Given Pliant Therapeutics' higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BNTC or PLRX more profitable? Benitec Biopharma's return on equity of -38.26% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Pliant Therapeutics N/A -67.56%-52.54% Do institutionals & insiders hold more shares of BNTC or PLRX? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 8.0% of Pliant Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBenitec Biopharma beats Pliant Therapeutics on 9 of the 15 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.38M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E Ratio-0.4321.3228.3920.08Price / SalesN/A280.80430.0899.95Price / CashN/A42.7636.2258.56Price / Book0.318.378.675.88Net Income-$210.30M-$55.19M$3.25B$258.89M7 Day Performance9.79%5.86%4.30%3.70%1 Month Performance20.77%17.29%10.57%11.71%1 Year Performance-88.26%4.39%35.68%17.98% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.3405 of 5 stars$1.57-1.3%$13.31+747.9%-88.2%$96.38MN/A-0.4390News CoverageBNTCBenitec Biopharma1.7592 of 5 stars$13.25+3.7%$23.83+79.9%+22.5%$347.81M$80K-8.7720GOSSGossamer Bio4.0047 of 5 stars$1.53+12.5%$8.25+439.2%+68.8%$347.77M$114.70M-6.65180Gap UpHigh Trading VolumeCMPSCOMPASS Pathways1.7339 of 5 stars$3.71+1.1%$17.00+358.2%-42.0%$347.11MN/A-1.86120Upcoming EarningsPRTAProthena3.736 of 5 stars$6.43+0.5%$31.50+389.9%-73.1%$346.11M$137.94M-3.09130ALTAltimmune2.102 of 5 stars$4.26+2.9%$18.20+327.2%-39.0%$345.53M$20K-3.3850AURAAura Biosciences2.6553 of 5 stars$6.75+5.5%$22.00+225.9%-29.6%$339.32MN/A-3.5550News CoverageRNACCartesian Therapeutics2.2984 of 5 stars$13.06-2.0%$40.00+206.3%-19.6%$338.91M$38.91M-0.2564News CoveragePositive NewsGap UpCAPRCapricor Therapeutics2.7297 of 5 stars$7.39-3.3%$22.56+205.2%+59.4%$337.58M$22.27M-5.20101Trending NewsGap UpAMRNAmarin0.2403 of 5 stars$16.10-4.9%$12.00-25.5%-2.7%$333.43M$228.61M-4.42360Upcoming EarningsINBXInhibrx Biosciences3.1485 of 5 stars$22.96+5.5%N/A+71.9%$332.46M$200K0.20166Positive News Related Companies and Tools Related Companies BNTC Alternatives GOSS Alternatives CMPS Alternatives PRTA Alternatives ALT Alternatives AURA Alternatives RNAC Alternatives CAPR Alternatives AMRN Alternatives INBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.